HIV infection. This persistence has led to the identification of many broadly neutralizing antibodies (bnAbs), [3] [4] [5] [6] which, although relatively rare in HIV-infected individuals, 7, 8 are nevertheless highly effective against most circulating strains and can prevent infection in robust animal models. [9] [10] [11] Therefore, although HIV infection does not induce protective antibody-mediated immunity, it is possible for the human immune system to produce antibodies that may, in principle, protect from HIV infection. This review will focus on the epitopes targeted by bnAbs and the methodologies used to identify them. In particular, as requested, we concentrate on our own efforts in the field with important developments in other laboratories included.
The first HIV bnAbs were isolated by our laboratory using phage display [12] [13] [14] and by Hermann Katinger's laboratory using human hybridoma electrofusion. 15, 16 These were the bnAbs b12 and 2F5. Later, the bnAbs 2G12 and 4E10 were described. [17] [18] [19] However, although these bnAbs proved very useful in answering questions about the interplay of HIV and nAbs, there was a definite lull in isolating new bnAbs. High-throughput neutralization assays were a major factor in changing that situation. The ability to analyze mAb and serum activity against large panels of viruses was demonstrated 20 and subsequently used to evaluate large numbers of HIV-infected donors in the International AIDS Vaccine Initiative (IAVI) Protocol G and C studies to identify those with exceptionally potent and broad sera, 8 map the specificities underlying these responses, 7, 21 and then isolate bnAbs from these individuals. [22] [23] [24] [25] [26] [27] [28] Independently, the standardization of the TZM-bl neutralization assay and the definition of neutralization sensitivity tiers [29] [30] [31] allowed much more rigorous serum analysis.
A second major factor in generating new bnAbs was the development of single B-cell approaches for the isolation of human antibod- 
| IDENTIFICATION OF HIV BNABS
An important step in the identification of HIV bnAbs was the ability to study large cohorts and identify those with potent and broad serum neutralizing activity. This was first achieved by defining criteria to rank 1800 HIV-positive serum samples from the IAVI Protocol G cohort for broad and potent activity against relatively neutralization-resistant isolates to represent circulating viruses. 8, 21 We selected and validated a six-virus cross-clade indicator panel and developed a scoring system wherein elite activity is defined as neutralization of at least one virus with an IC 50 value of more than 1:300 across a minimum of four different clades. 8 Having identified HIV-positive donors with broad and potent neutralizing activity, the next step was to isolate the monoclonal Abs (mAbs) giving rise to this phenotype. Given the limited efficiency of both B-cell immortalization and phage display, we opted to directly screen stimulated single B-cell supernatants. This approach used a strategy that required adaption to a high-throughput format to screen enough B cells to identify rare HIV bnAbs (Figure 1 ).
In the first experiment, we screened more than 30 000 individual B cells from one donor for the ability to neutralize two HIV strains and also bind to recombinant gp120 and gp41 protein subunits 23 ( This approach of high-throughput neutralization screening of single B-cell cultures was re-employed to isolate bnAbs from multiple donors (Table 1) . These bnAbs comprise the PGT121, PGT128, PGT135, PGT145, and PGT151 families, 22, 25 which are among the most potent bnAbs isolated to date, with PGT121 found to be protective at low doses in an in vivo challenge model. 35 Similar large single B-cell culture screens led to the identification of the highly potent and broad 10E8, a gp41 membrane proximal region (MPER)-specific bnAb 36 and 35022, which binds the gp120-gp41 interface, 37 from the same donor. All of these studies operated on the basis that the neutralization specificity of the donor serum was unknown, and therefore, any Ab isolation method should not be biased by the use of pre-enrichment for binding activity.
However, simultaneous advances in our ability to discern the specificities that mediate elite neutralization 21 advocated for the use of a recombinant Env protein as bait for bnAb B cells. This method was used to identify multiple Ab lineages from six donors but did not identify any with bnAb activity. 38 In contrast, the bnAb VRC01 was identified using a resurfaced Env gp120 subunit (RSC3) bait that preferentially bound the previously isolated bnAb b12 and was recognized by the individual donor's neutralizing serum 39 ( Figure 1 , Table 1 ). RSC3 was fluorescently labeled and mixed with donor cells so that RSC3-positive B cells could be separated by fluorescence-activated cell sorting (FACS) into individual wells. cDNA was generated from each well and heavy-and light-chain pairs cloned, recombinantly expressed and then screened for neutralization activity. Similar approaches with different baits were used to isolated additional gp120-specific bnAbs including 3BNC117, 3BNC60, 40 and 10-1074. 41 In this method, selection is based purely on the ability to bind the Env bait, and many non-neutralizing mAbs may also be cloned unless there is counter selection with an epitopespecific knockout probe. We successfully used this approach to isolate the PCDN series of bnAbs from a protocol C donor, whose serum neutralization activity was N332 dependent, enabling counter selection with a 332 glycan knockout negative probe. 26 However, it should be noted that this strategy selects for bnAbs with a stringent requirement for an N332 glycan and will not select for antibodies that can use nearby glycans interchangeably with the N332 glycan, as found for the PGT121 family bnAbs.
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Many of the bnAbs identified by screening B-cell cultures are trimer-preferring or -specific, such as PG9 and PGT151, and as such, (Table 1) . It should be noted, however, that the bnAb 8ANC195 was isolated by selection with a gp120 core protein 40 but was later revealed to bind an area spanning the gp120-gp140 interface rather than exclusively gp120. 43 To counter the limitation of binding selection based on the gp120 subunit, Env on the surface of cells was used as a bait to select the bnAbs 3BC315 and 3BC176, 44 which are also specific for the gp120-gp41 trimer interface. 45 Subsequently, advances in the production of soluble near-native stabilized Env trimers 46 have allowed better selection of Env-specific B cells, excluding those which bind regions not exposed on the infectious viral spike.
Using this method, we isolated PGDM1400 28 from the same donor that previously yielded the PGT141-145 family of bnAbs via the Bcell culturing approach. 22 Furthermore, stabilized BG505 SOSIP.664
trimers have been used as baits to isolate two bnAbs which occupy overlapping epitopes at the gp120-gp41 interface and also contact the fusion peptide, ACS202 47 and VRC34. 48 Similarly, additional apexspecific bnAbs were recently isolated from the CAP256 donor using both the BG505 SOSIP.664 trimer and B-cell culture. 49 However, the most potent new bnAb was found by the latter method, leading the authors to emphasize the advantages of this method. amino acid mutation but still notable neutralization breadth. 50 Studies by other groups have identified bnAbs including CAP256, 51 CH103, 52 and CH235 53 that highlight the extensive viral epitope diversification and interplay between B-cell lineages during the co-evolution of virus and bnAbs. Similarly, our study of an N332-dependent Protocol C donor yielded a family of bnAbs and precursors from 16 to 38 months post infection. 26 The development of the bespoke Ab analysis platform Clonify 54 enabled us to filter these data for PCDN Abs and identify a likely unmutated common ancestor (UCA) of the lineage and revealed that there was a virus-triggered selection bottleneck in Ab maturation after 27 months. Thus, the application of NGS techniques to study B-cell repertoires from peripheral lymphocytes has greatly increased our understanding of bnAb development. However, it is important to note that at least one individual bnAb must first be identified and validated experimentally; otherwise, it is generally not possible to decipher which rare B-cell transcripts encode bnAbs. There have been attempts to mine NGS B-cell repertoire data by predicting heavy-and T A B L E 1 BnAb specificity and isolation method was required. Heavy chains, which were functional, were then paired with donor light chains encoding the characteristic five-amino-acid sequence motif of VRC01. 58 However, such an approach is not trivial and is not applicable to donors with undefined specificities.
| SPECIFICITY OF HIV BNABS
The ability to identify bnAbs over the last decade has dramatically increased our knowledge of the specificities underlying broad and potent neutralization of HIV. 3 In turn, this has allowed more thorough pre-screening of potential bnAb donor serum samples. If the specificity of a neutralizing response can be determined, it can help to decide whether a binding or neutralization-based selection method is the best option to isolate bnAbs (Table 1 ). There is also now a greater understanding of the frequency and distribution of bnAb epitopes, both within individual patients and across cohorts. 59 However, there may remain additional epitopes to identify as shown by the serological analysis of protocol C, the most diverse longitudinal primary infection cohort studied to date. This study revealed that the bnAb specificity of 12% of the 439 donors is unknown. 7 Where the specificity could be determined in the top-ranking neutralizing donors, the majority of bnAb specificities mapped to glycan-dependent epitopes, including the apex, high-mannose patch, and PGT151-like gp120-gp41 interface epitopes. 7 It is especially noteworthy that all of these epitopes were originally defined by bnAbs discovered by direct neutralization screening rather than antigen selection (Table 1) . Only one top-ranking neutralizing donor exhibited a CD4-binding site dependent bnAb response, while many donors made type-specific CD4-binding site responses, 7 in agreement with other studies. 60 However, it should be noted that CD4-binding site bnAbs typically display very high levels of somatic hypermutation, which may necessitate a longer post-infection time period to develop than typically studied. Indeed, CD4-binding site bnAb activity emerged in only one subject at 66 months in the protocol C study. 7 Of note, other studies have suggested a greater proportion of bnAb serum responses to target the CD4-binding site. 21, 61, 62 Thus, while the serum neutralizing specificity of new donors can often be identified, there may be cases where serum profiles appear similar to previously studied donors, but the nuances of a particular individual's bnAb response differ. In turn, this may mean that a typical isolation strategy could risk missing novel bnAbs that target known epitopes in different ways. This idea is suggested by the complexity with which existing bnAb families target their shared epitopes in subtly different ways. These differences are outlined below for the major classes identified to date, namely, those targeting the trimer apex, highmannose patch, CD4-binding site, gp120-gp41 interface, and MPER.
The first class of bnAbs targeting a shared site, but with subtle differences in the exact epitope bound, is the trimer apex-binding Abs (Figure 2 ). The pioneering examples of this class are PG9 and PG16, 23 which we showed bind to a novel trimer-preferring, glycan-dependent bnAb epitope. [63] [64] [65] The glycan site at residue 160 is typically critical for these bnAbs and a decrease in neutralization is seen when additional glycan sites are removed from the V1, V2, and V3 loops in a viral isolate-dependent manner. 66 With the isolation of additional N160-dependent apex bnAbs, by our group and others, 22,42,51,67 this class can be divided into four groups typified by the prototypes PG9, CH01, PGT145, and CAP256.VRC26.09 (CAP256.09). 68 All four prototypes bind N160 and basic residues in the lysine-rich strand C of the V2 loop, but the exact residues required for each epitope vary, with a lysine at position 169 the most commonly shared feature. 68 Furthermore, while N160 is absolutely required for only three out of four prototypes, CAP256.09 is only partially dependent on a glycan at this position. 51, 68 There are also differences in the particular glycans preferred by each prototype, with variations even between PG9 and PG16, which prefer glycans with α-2-3 and α-2-6 linked sialic acid terminal sugars, respectively. 68, 69 In addition, we found that virus produced in the presence of kifunensine, resulting in untrimmed high-mannose glycans, is not neutralized by PG9/16. 66 These bnAbs are also sensitive to natural glycan heterogeneity, which means a fraction of virions may be resistant to neutralization because they contain glycoforms that are not recognized by the Abs, resulting in incomplete neutralization curves. 66 We have also observed this phenomenon with additional apex bnAbs such as the potent PGDM1400 28 and also many other bnAb specificities.
This effect varies with different bnAb and viral isolate combinations.
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However, the extent to which incomplete neutralization is observed with serum samples remains to be determined.
F I G U R E 2 Epitope regions targeted
by HIV bnAbs. Model based on the fully glycosylated BG505 SOSIP.664 trimer constructed using PDB: 4ZMJ. 103 The gp120 and gp41 subunits are colored light gray and dark grey respectively. The five bnAb epitope regions are labeled as follows: the apex site is colored purple, the high-mannose patch is colored magenta, the CD4bs is colored green, the gp120-gp41 region is colored red, and MPER is colored yellow
The second class of bnAbs to consider is made up of those binding the high-mannose patch on the gp120 subunit of the Env trimer ( Figure 2 but it did not always do so for all virus strains and N301 was also implicated. 22 Further investigation revealed that the high-mannose patch bnAbs exhibit a degree of promiscuity for different glycan sites across the epitope, allowing them to maintain neutralization breadth in the face of viral changes to glycosylation sites. 28 The level of permissiveness for different glycan sites varies among the members of this bnAb class, for example, moving the glycan site from 332 to 334 in a six-virus panel has no effect on PGT128, prevents neutralization of two of four viruses by PGT121, and renders PGT135 unable to neutralize any virus. 28 Furthermore, within bnAb families, viral variability is tolerated to different degrees due to structural differences. PGT128
and PGT130 belong to branches of the same bnAb family, but due to a six-residue insertion, PGT128 is better able to accommodate glycan location and heterogeneity in the V1 loop than PGT130.
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The third class of bnAbs target the CD4-binding site ( Figure 2 ) and have been predominantly isolated by a binding-based selection using proteins designed to isolate bnAbs from donors where this specificity is apparent in the serum neutralization profile. 39 This approach negates the need to screen thousands of individual B-cell culture supernatants and allows a more streamlined process for isolating bnAbs. The first CD4-binding site bnAb isolated, apart from b12, 12 was VRC01, which partially mimics the binding of CD4 to its receptor site. 74 The RSC3 bait used to capture the VRC01 B-cell lineage was modified to preferentially bind b12 and a negative bait that could not bind b12 was used for counter selection. 39 This strategy was re-utilized to isolate PGV04 from a separate donor. This bnAb, in contrast to VRC01, does not induce conformational changes in gp120 upon binding. 25 Many additional CD4-binding site bnAbs were isolated using RSC3 56 or other Env baits 40 and one by EBV immortalization of B cells followed by an ELISAbased binding screen. 75 Structural studies have enabled comparison of the CD4-binding site bnAbs and the definition of two subclasses:
those that bind predominantly using their CDRH3 and those that are genetically restricted and use either the VH1-2 or VH1-46 V gene. 76 Within the genetically restricted subclass, the potent VRC01-like antibodies use only the VH1-2 V gene and also share an unusual short light chain motif, unlike VH1-46 V gene bnAbs. 57, 76, 77 Recently, it has been shown that while VRC01-like heavy chains can mature relatively rapidly, generation of light chains that are able to accommodate glycans obstructing access to the epitope takes longer. 78 In contrast, the CD4-binding site bnAbs that bind via their CDRH3 are drawn from a wide variety of V genes, have no conserved binding motif, but approach the trimer from similar angles. 76 In summary, the CD4 binding site is recognized by bnAbs that show, in detail, divergent modes of binding but that are clustered around the two molecular solutions described above. 76 The fourth class of bnAb is a highly divergent set, derived from multiple donors by a variety of methods, but all members of the class target the gp120-gp41 interface (Figure 2 ). Despite this, the epitopes are not completely overlapping and many do not compete with one another in the same way that apex and high-mannose patch bnAbs do, which is in agreement with negative-stain microscopy data showing their distribution across the trimer interface. 47 Many gp120-gp41
interface bnAbs have been isolated in rapid succession over the last few years, 24, 37, 47, 48 and some previously identified bnAbs 44 have been
shown to bind to this region. 45, 79 The first bnAb shown to bind this region was PGT151 and was again isolated by our large-scale screen of single B-cell culture supernatants for neutralization activity. 24 This bnAb is highly specific for cleaved pre-fusion Env and potently neutralizes via interaction with complex tri-and tetra-antennary glycans at positions 611 and 637 within gp41 24 and protein residues K490, T499, R500, R503 in gp120. 80 Shortly after, bnAb 35022 was isolated, also by selecting for neutralization activity, and found to be trimerspecific. It also binds the gp120-gp41 interface although at a site closer to the viral membrane than PGT151. 37 35022 is predicted to be orientated parallel to the membrane and, unlike PGT151, is not cleavage specific. 37 Coincidental with the discovery of these two new specificities, two previously identified bnAbs, 3BC315 and 3BC176, for which the epitope was not originally delineated 44 were found to bind to an area partially overlapping with 35022. 45 However, unlike 35022, the binding of these two bnAbs results in destabilization of the trimer.
Similarly, a bnAb isolated using a gp120 bait strategy, 8ANC195 40 was found to also bind the gp120-gp41 interface, and to bind to glycans at 276, 234, and 637, with a footprint falling between those of PGT151 and 35022. 37, 43 Strikingly, this bnAb can bind to Env both in a closed conformation and partially reverse the open-conformation induced by concomitant CD4 binding. 79 Most recently, two additional trimerspecific bnAbs, ACS202 and N123-VRC34.01, were isolated and found to bind to yet another distinct part of the gp120-gp41 interface and to contact the fusion peptide. 47, 48 The differences between the members of this class of bnAbs, particularly with regard to different conformational requirements for trimer binding, highlight how a bait strategy based on any one of these observations alone may have reduced the likelihood of isolating the other gp120-gp41 interface bnAbs.
The fifth class of bnAbs comprise those which target the MPER ( Figure 2) ; namely 10E8, which was selected by single B-cell culture and screening for neutralization 36 ; and 2F5 and 4E10, which were isolated by a hybridoma approach. 16, 18, 19, 81 The latter two Abs were isolated prior to PG9/16 and although they have quite extensive breadth are not as potent as most of the Abs described herein as bnAbs. Interestingly, 4E10, and to a much lesser degree 2F5, exhibit polyreactivity in vitro [82] [83] [84] but were shown to be protective and non-pathogenic during an in vivo challenge study. 85 However, 2F5 and 4E10 transgenic mice have greatly impaired B-cell development as 95% of cells fail to complete the pre-B to immature B-cell transition. 86 The minority of B cells which circumvent this checkpoint are anergic, but yet can still be activated by an MPER immunogen. 86 The more recently isolated MPER bnAb 10E8
is highly potent and does not display any autoreactivity nor does it bind lipids as has been reported for other MPER Abs. 87 This may be because 10E8 approaches MPER from an altered angle and uses a different binding mode to 4E10. 36 Serum analysis suggested 10E8-like specificities were not unusual, with 27% of 78 donors exhibiting this activity.
However, to date, only one potent MPER bnAb has been identified, and additional work is needed to isolate more MPER bnAbs so that this area of vulnerability can be more fully understood by defining differences between MPER bnAbs as is underway for the other bnAb classes.
| CONCLUSIONS
Given the great progress over the past decade in isolating bnAbs and studying their modes of action, an obvious question is do we still except in transgenic mouse models [95] [96] [97] [98] [99] and camelids. 100, 101 However, isolation of neutralizing Abs from immunized rabbits has already provided an explanation for the limited serum neutralization breadth observed to date with one near-native Env preparation 88, 93 : namely, that isolate-specific glycan holes can be highly immunogenic and the target of the majority of the autologous Tier 2 serum responses observed.
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Therefore, it seems probable that, without a major improvement in the potency and breadth of the serum response, establishing whether even a small proportion of the response is bnAb-like will require higher resolution Ab isolation methods with even greater throughput.
Following the identification of PG9 and PG16 in 2009 and the many other bnAbs that came after, it has become possible to design immunogens based on our knowledge of these extraordinary antibodies. The hope is that by tailoring immunogens to elicit bnAbs rather than strain-specific and non-neutralizing Abs, it will be possible to elicit broad and potent immune responses. 
